29th Annual Prostate Cancer Foundation Scientific Retreat

October 27 - 29, 2022

Omni La Costa Resort
Carlsbad, California
GENERAL SESSIONS

Location: Costa Del Sol Ballroom

8:00 AM  Registration  Costa Del Sol Foyer

Welcome & Opening Remarks  1:00 PM - 1:05 PM

Howard Soule, PhD  Prostate Cancer Foundation
Andrea Miyahira, PhD  Prostate Cancer Foundation

Session 1: Novel Clinical Trial Updates  1:05 PM - 2:25 PM

Moderator: Jake Vinson, MHA  The Prostate Cancer Clinical Trials Consortium

1:05 PM - 1:20 PM  Biomarker Results from Targeting TROP2 with Sacituzumab Govitecan in mCRPC  Joshua Lang, MD  University of Wisconsin

1:20 PM - 1:25 PM  Discussion

1:25 PM - 1:40 PM  Targeting Myeloid Chemotaxis via CXCR2 Blockade as a Therapeutic Strategy in Advanced Prostate Cancer  Christina Guo, MD  Institute for Cancer Research; Royal Marsden Hospital, UK

1:40 PM - 1:45 PM  Discussion
Thursday, October 27, 2022

1:45 PM - 2:00 PM  Targeting a Tumor-Specific CD46 Epitope in Metastatic Castration Resistant Prostate Cancer
Rahul Aggarwal, MD
University of California, San Francisco

2:00 PM - 2:05 PM  Discussion

2:05 PM - 2:20 PM  TRITON3 Update: A Phase 3 Study of Rucaparib vs. Physician’s Choice of Therapy in mCRPC associated with HRD
Alan Bryce, MD
Mayo Clinic

2:20 PM - 2:25 PM  Discussion

SPECIAL LECTURE
2:25 PM - 2:45 PM

The Magic of Mayonnaise
Kenneth Pienta, MD
Johns Hopkins University

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

2:45 PM - 2:50 PM  Discussion

2:50 PM - 2:55 PM  Break

PANEL: State of Science on Diet and Lifestyle in Lethal Prostate Cancer and Survivorship
2:55 PM - 3:55 PM
Moderator: Lorelei Mucci, ScD
Harvard TH Chan School of Public Health

Panelists:
William Aronson, MD (University of California, Los Angeles)
June Chan, ScD (University of California, San Francisco)
Christina Dieli-Conwright, PhD, MPH (Dana-Farber Cancer Institute)
Edward Giovannucci, MD, ScD (Harvard TH Chan School of Public Health)
3:55 PM - 4:00 PM  Break

---

**KEYNOTE ADDRESS**
4:00 PM - 5:00 PM

**Michael Milken**
Founder and Chairman
Prostate Cancer Foundation

*Introduced by Stuart Holden, MD*
Prostate Cancer Foundation

---

**Group Photo**
5:00 PM - 5:15 PM

*Location: Costa Del Sol Foyer*

---

5:15 PM - 7:00 PM  Break
Thursday, October 27, 2022

Dinner and Awards Ceremony
7:00 PM - 10:00 PM

Location: Costa Del Sol Ballroom

PCF Awards Ceremony
8:00 PM - 9:00 PM

2020 PCF Young Investigator Awards

2021 PCF Young Investigator Awards

2022 PCF Young Investigator Awards

2022 PCF VAlor Precision Oncology Center of Excellence Awards

2020 PCF Challenge Awards

2021 PCF Challenge Awards

2022 PCF Challenge Awards
Friday, October 28, 2022

6:00 AM - 6:45 AM  Breakfast
Location: Costa Del Sol Patio

6:45 AM - 7:00 AM  Move to Session

GENERAL SESSIONS
Location: Costa Del Sol Ballroom

PANEL:  State of Clinical Therapy for Advanced Prostate Cancer
7:00 AM - 8:00 AM
Moderator: Charles Ryan, MD
Prostate Cancer Foundation

Panelists:
Jessica Hawley, MD, MS (University of Washington; Fred Hutchinson Cancer Center)
Renu Eapen, MBBS, FRACS (Urol) (Peter MacCallum Cancer Centre, Melbourne; University of Melbourne)
Felix Feng, MD (University of California, San Francisco)
Michael Haffner, MD, PhD (University of Washington; Fred Hutchinson Cancer Center)
Ana Kiess, MD, PhD (Johns Hopkins University)
Colin Pritchard, MD, PhD (University of Washington; Fred Hutchinson Cancer Center)

8:00 AM - 8:05 AM  Break

Session 2: Impact of Molecular and Genomic Factors on Prostate Cancer Disease
Etiology and Health Disparities
8:05 AM – 9:25 AM
Moderator: Salma Kaochar, PhD
Baylor College of Medicine

8:05 AM - 8:20 AM  Immunogenomic Landscape of African-American Prostate Cancer
Tamara Lotan, MD
Johns Hopkins University

8:20 AM - 8:25 AM  Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Presenter(s)</th>
<th>Affiliation</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:25 AM - 8:40 AM</td>
<td>Alternative RNA Splicing in African American Prostate Cancer</td>
<td>Steven Patierno, PhD</td>
<td>Duke University</td>
<td></td>
</tr>
<tr>
<td>8:40 AM - 8:45 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:45 AM - 9:00 AM</td>
<td>Epidemiology: Are Biologic Impacts Due to Ancestry vs Socioeconomic impacts of Racism?</td>
<td>Folakemi Odedina, PhD</td>
<td>Mayo Clinic</td>
<td></td>
</tr>
<tr>
<td>9:00 AM - 9:05 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:05 AM - 9:20 AM</td>
<td>Reprogramming of AR in African American Prostate Cancer</td>
<td>Salma Kaochar, PhD</td>
<td>Baylor College of Medicine</td>
<td>(*N/A post-meeting for On Demand)</td>
</tr>
<tr>
<td>9:20 AM - 9:25 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Session 3: Neuroendocrine Prostate Cancer</strong> 9:25 AM - 10:25 AM</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:25 AM - 9:40 AM</td>
<td>Circular RNA in NEPC and CRPC</td>
<td>Hansen He, PhD</td>
<td>Princess Margaret Cancer Centre, Canada</td>
<td></td>
</tr>
<tr>
<td>9:40 AM - 9:45 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:45 AM - 10:00 AM</td>
<td>The Role of ASCL1 in NE Reprogramming of Prostate Cancer</td>
<td>John Lee, MD, PhD</td>
<td>Fred Hutchinson Cancer Center</td>
<td></td>
</tr>
<tr>
<td>10:00 AM - 10:05 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05 AM - 10:20 AM</td>
<td>PSMA Heterogeneity in NEPC and CRPC</td>
<td>Himisha Beltran, MD</td>
<td>Dana-Farber Cancer Institute</td>
<td></td>
</tr>
<tr>
<td>10:20 AM - 10:25 AM</td>
<td>Discussion</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**Session 4: Single Cell Sequencing**

10:25 AM – 11:25 AM

**Moderator: Michael Shen, PhD**
Columbia University

10:25 AM - 10:40 AM

*Longitudinal Single-Cell Analysis of Metastases from Men with mHSPC Treated with ADT and Anti-PD-1*

Jessica Hawley, MD, MS
University of Washington; Fred Hutchinson Cancer Center

10:40 AM - 10:45 AM Discussion

10:45 AM - 11:00 AM

*Harnessing Single Cell Analysis of the Tumor Microenvironment to Improve Immunotherapy Approaches in Prostate Cancer*

Amy Moran, PhD
Oregon Health Sciences University

11:00 AM - 11:05 AM Discussion

11:05 AM - 11:20 AM

*Heterogeneity and Complexity of the Prostate Epithelium: New Findings from Single-Cell RNA Sequencing Studies*

Michael Shen, PhD
Columbia University

(*N/A post-meeting for On Demand)

11:20 AM - 11:25 AM Discussion

---

**SPECIAL LECTURE**

11:25 AM - 11:55 AM

*The Global Public Square of Prostate Cancer*

Charles J. Ryan, MD
Prostate Cancer Foundation

Introduced by Howard Soule, PhD
Prostate Cancer Foundation

11:55 AM - 12:00 PM Discussion
**Friday, October 28, 2022**

**Lunch**  
**12:00 PM - 12:50 PM**  
*Location: Costa Del Sol Patio*

12:50 PM - 1:00 PM  **Move to Session 5**  
*Location: Costa Del Sol Ballroom*

**SPECIAL LECTURE**  
**1:00 PM - 1:15 PM**  
**Rational Combinations with Androgen Receptor Inhibition for Prostate Cancer Treatment**

**Jeff Settleman, PhD**  
Chief Scientific Officer, Oncology R&D, Pfizer  
(*N/A post-meeting for On Demand*)

*Introduced by Howard Soule, PhD*  
Prostate Cancer Foundation

1:15 PM - 1:20 PM  **Discussion**
**Session 5: Lessons from Primary Prostate Cancer**

1:20 PM - 2:40 PM

**Moderator:** Jiaoti Huang, PhD  
Duke University

1:20 PM - 1:35 PM  
*Molecular Signatures to Risk-Stratify Intermediate-Risk Primary Prostate Cancer*  
Jiaoti Huang, PhD  
Duke University

1:35 PM - 1:40 PM  
Discussion

1:40 PM - 1:55 PM  
*Cellular Origins of Therapy Resistance / Biologic Features in Primary Prostate Cancer that may Inform Outcome or Therapy Response*  
Mary-Ellen Taplin, MD  
Dana-Farber Cancer Institute

1:55 PM - 2:00 PM  
Discussion

2:00 PM - 2:15 PM  
*Predicting Prostate Cancer Outcome and Molecular Subtype with Artificial Intelligence*  
Tamara Lotan, MD  
Johns Hopkins University

2:15 PM - 2:20 PM  
Discussion

2:20 PM - 2:35 PM  
*Lineage Plasticity in Cancers of the Lung and Prostate*  
Charles Rudin, MD, PhD  
Memorial Sloan Kettering Cancer Center

2:35 PM - 2:40 PM  
Discussion

---

**Session 6: Genetic, Epigenetic, Epitranscriptomic and Post-Translational Mechanisms and Clinical Heterogeneity in Prostate Cancer**

2:40 PM - 3:40 PM

**Moderator:** Nigel Mongan, PhD  
The University of Nottingham, UK

2:40 PM - 2:55 PM  
*Genetic Determinants of Clinical Heterogeneity in Prostate Cancer*  
Brian Robinson, MD  
Weill Cornell Medicine

2:55 PM - 3:00 PM  
Discussion
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>3:00 PM - 3:15 PM</td>
<td>Epitranscriptomic and Epigenetic Determinants of Prostate Cancer</td>
<td>Jennie Jeyapalan, PhD</td>
<td>The University of Nottingham, UK</td>
</tr>
<tr>
<td>3:15 PM - 3:20 PM</td>
<td>Discussion</td>
<td></td>
<td>(*N/A post-meeting for On Demand)</td>
</tr>
<tr>
<td>3:20 PM - 3:35 PM</td>
<td>Post-Transcriptional Regulation of Androgen Receptor During Prostate Cancer Progression</td>
<td>Charlotte Bevan, PhD</td>
<td>Imperial College London, UK</td>
</tr>
<tr>
<td>3:35 PM - 3:40 PM</td>
<td>Discussion</td>
<td></td>
<td>(*N/A post-meeting for On Demand)</td>
</tr>
<tr>
<td>3:40 PM - 5:00 PM</td>
<td>Session 7: Next Generation Prostate Cancer Theranostics and Combination Therapies</td>
<td>Moderator: Ana Kiess, MD, PhD</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>3:40 PM - 3:55 PM</td>
<td>Immunomodulation of Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate Response to Combination Therapies</td>
<td>Zachary Morris, MD, PhD</td>
<td>University of Wisconsin</td>
</tr>
<tr>
<td>3:55 PM - 4:00 PM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM - 4:15 PM</td>
<td>Combination of PSMA-targeted Radiopharmaceutical Therapy and Immunotherapy for mCRPC</td>
<td>Shahneen Sandhu, MBBS</td>
<td>Peter MacCallum Cancer Centre, Australia</td>
</tr>
<tr>
<td>4:15 PM - 4:20 PM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:20 PM - 4:35 PM</td>
<td>hK2 Targeted Radioimmunotheranostics for Prostate Cancer</td>
<td>David Ulmert, MD, PhD</td>
<td>University of California, Los Angeles</td>
</tr>
<tr>
<td>4:35 PM - 4:40 PM</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:40 PM - 4:55 PM</td>
<td>Combinations of Radiopharmaceutical Therapies and SBRT for Oligometastatic Hormone-Sensitive Prostate Cancer</td>
<td>Ana Kiess, MD, PhD</td>
<td>Johns Hopkins University</td>
</tr>
<tr>
<td>4:55 PM - 5:00 PM</td>
<td>Discussion</td>
<td></td>
<td>(*N/A post-meeting for On Demand)</td>
</tr>
</tbody>
</table>
**Session 8: Investigating the Path from PI3K to Protein Synthesis to Tailor Prostate Cancer Therapy**
5:00 PM - 6:00 PM

**Moderator:** Daniela Brina, PhD
Institute of Oncology Research, Switzerland

5:00 PM - 5:15 PM  
*Therapeutic Targeting of the Translational Machinery Blocks MDSCs and Enhances Anti-Tumor Immunity in Prostate Cancer*

Daniela Brina, PhD
Institute of Oncology Research, Switzerland

5:15 PM - 5:20 PM  
Discussion

5:20 PM - 5:35 PM  
*Defining the Therapeutic Selective Dependencies for Distinct Subtypes of PI3K Pathway-Altered Prostate Cancers*

Brett Carver, MD
Memorial Sloan Kettering Cancer Center

5:35 PM - 5:40 PM  
Discussion

5:40 PM - 5:55 PM  
*The Androgen Receptor Regulates a Druggable Translational Regulon in Advanced Prostate Cancer*

Andrew Hsieh, MD
Fred Hutchison Cancer Center

5:55 PM - 6:00 PM  
Discussion

---

**Dinner**
6:30 PM - 7:30 PM

*Dinner Location: Costa Del Sol Patio*

**Poster Session and Dessert**
7:30 PM - 10:30 PM

*Poster Session and Dessert Location: Costa De La Luna Ballroom*
Saturday, October 29, 2022

6:00 AM - 6:45 AM  Breakfast
Location: Costa Del Sol Patio

6:45 AM - 7:00 AM  Move to Session

GENERAL SESSIONS
Location: Costa Del Sol Ballroom

Session 9: Combining Immunomodulatory Treatments for Prostate Cancer
7:00 AM - 8:40 AM
Moderator: Nicholas Huntington, PhD
Monash University, Australia

7:00 AM - 7:15 AM  Targeting P53 to Induce ICB Response in Cold Tumors
Nicholas Huntington, PhD
Monash University, Australia

7:15 AM - 7:20 AM  Discussion

7:20 AM - 7:35 AM  Engaging FLT3 to Promote Dendritic Cell Expansion & Drive the
Adaptive Anti-Tumor Immune Response
Michelle Kuhne, PhD
Gilead Sciences

7:35 AM - 7:40 AM  Discussion

7:40 AM - 7:55 AM  Leveraging an Interplay Between Hormone Receptor Signaling
and Immune Recognition to Enhance Immunotherapy in
Prostate Cancer
Lisa Chesner, PhD
University of California, San Francisco

7:55 AM - 8:00 AM  Discussion

8:00 AM - 8:15 AM  EZH2 Inhibition Reprograms the Tumor Microenvironment to
Potentiate Response to Checkpoint Inhibition
Leigh Ellis, PhD
Cedars Sinai Medical Center

8:15 AM - 8:20 AM  Discussion

8:20 AM - 8:35 AM  CoStimulatory Bispecifics for Prostate Cancer Immunotherapy
Israel Lowy, MD, PhD
Regeneron Pharmaceuticals Inc.

8:35 AM - 8:40 AM  Discussion
Saturday, October 29, 2022

Session 10: Lessons from Other Cancers  
8:40 AM - 10:00 AM

**Moderator: Peter Nelson, MD**  
Fred Hutchinson Cancer Center

8:40 AM - 8:55 AM  
**MMR and Immunoablative Therapy**  
Luis Diaz, MD  
Memorial Sloan Kettering Cancer Center

8:55 AM - 9:00 AM  
Discussion

9:00 AM - 9:15 AM  
**Spatial and Single Cell Profiling of Breast Cancer through Neoadjuvant Therapy**  
Christina Curtis, PhD, MSc  
Stanford University

9:15 AM - 9:20 AM  
Discussion

9:20 AM - 9:35 AM  
**Drivers of Merkel Cell Carcinoma Provide Insight into Neuroendocrine Prostate Cancer**  
James DeCaprio, MD  
Dana-Farber Cancer Institute

9:35 AM - 9:40 AM  
Discussion

9:40 AM - 9:55 AM  
**Collective Signaling Factors Driving Breast Cancer Metastasis and Therapy Resistance**  
Kevin Cheung, MD  
Fred Hutchinson Cancer Center  (*N/A post-meeting for On Demand)

9:55 AM - 10:00 AM  
Discussion

Session 11: Novel Gamma Delta T Cell Therapy Platforms for Oncology  
10:00 AM - 11:45 AM

**Moderator: Marco Gottardis, PhD**  
Janssen Research & Development, LLC

10:00 AM - 10:05 AM  
**Introduction**  
Marco Gottardis, PhD  
Janssen Research & Development, LLC

10:05 AM - 10:20 AM  
**Primer on the Biology of γδ T cells and their Use in Cancer Cell Therapy**  
Sandy Hayes, PhD  
Janssen

10:20 AM - 10:25 AM  
Discussion
10:25 AM - 10:40 AM Novel γδ T Cell Therapy Platform
Lawrence Lamb, Jr., PhD
IN8bio

10:40 AM - 10:45 AM Discussion

10:45 AM - 11:00 AM Bispecific γδ T Cell Engagers for the Treatment of Prostate Cancer
Paul Parren, PhD
LAVA Therapeutics

11:00 AM - 11:05 AM Discussion

11:05 AM - 11:20 AM Using iPSC-derived γδ CAR-T cells to Overcome the TME barrier in Solid Tumors
Hy Levitsky, MD
CENTURY TX

11:20 AM - 11:25 AM Discussion

11:25 AM - 11:40 AM Progress with γ/δ T Cell Therapy in the Treatment of Cancer
Blake Aftab, PhD
Adicet Bio, Inc. (*N/A post-meeting for On Demand)

11:40 AM - 11:45 AM Discussion

Closing Remarks
11:45 AM - 12:00 PM
Howard Soule, PhD
Prostate Cancer Foundation
Andrea Miyahira, PhD
Prostate Cancer Foundation

Meeting Adjourned
** A boxed lunch will be provided **
Program Committee:

Program Committee Co-Chair: Howard Soule, PhD (Prostate Cancer Foundation)
Program Committee Co-Chair: Andrea Miyahira, PhD (Prostate Cancer Foundation)

Charles Ryan, MD (Prostate Cancer Foundation)
Himisha Beltran (Dana-Farber Cancer Institute)
Daniela Brina, PhD (Institute of Oncology Research, Switzerland)
Marco Gottardis, PhD (Janssen Research & Development, LLC)
Jessica Hawley, MD, MS (University of Washington; Fred Hutchinson Cancer Center)
Jiaoti Huang, PhD (Duke University)
Nicholas Huntington, PhD (Monash University, Australia)
Salma Kaochar, PhD (Baylor College of Medicine)
Anna Kiess, MD (Johns Hopkins University)
Nigel Mongan, PhD (The University of Nottingham)
Peter Nelson, MD (Fred Hutchinson Cancer Center)
Michael Shen, PhD (Columbia University)
Jake Vinson, MHA (The Prostate Cancer Clinical Trials Consortium)
We deeply thank our Retreat supporters for providing funding for this educational initiative.